Evaluation of novel Epstein-Barr virus-derived antigen formulations for monitoring virus-specific T cells in pediatric patients with infectious mononucleosis.
Epstein-Barr virus
Immune monitoring
Infectious mononucleosis
Pediatric patients
T-cell response
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
19
07
2023
accepted:
06
06
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
Infection with the Epstein-Barr virus (EBV) elicits a complex T-cell response against a broad range of viral proteins. Hence, identifying potential differences in the cellular immune response of patients with different EBV-associated diseases or different courses of the same disorder requires interrogation of a maximum number of EBV antigens. Here, we tested three novel EBV-derived antigen formulations for their ability to reactivate virus-specific T cells ex vivo in patients with EBV-associated infectious mononucleosis (IM). We comparatively analyzed EBV-specific CD4+ and CD8+ T-cell responses to three EBV-derived antigen formulations in 20 pediatric patients during the early phase of IM: T-activated EBV proteins (BZLF1, EBNA3A) and EBV-like particles (EB-VLP), both able to induce CD4+ and CD8+ T-cell responses ex vivo, as well as an EBV-derived peptide pool (PP) covering 94 well-characterized CD8+ T-cell epitopes. We assessed the specificity, magnitude, kinetics, and functional characteristics of EBV-specific immune responses at two sequential time points (v1 and v2) within the first six weeks after IM symptom onset (T All three tested EBV-derived antigen formulations enabled the detection of EBV-reactive T cells during the early phase of IM without prior T-cell expansion in vitro. EBV-reactive CD4+ and CD8+ T cells were mainly mono-functional (CD4+: mean 64.92%, range 56.15-71.71%; CD8+: mean 58.55%, range 11.79-85.22%) within the first two weeks after symptom onset (v1) with IFN-γ and TNF-secreting cells representing the majority of mono-functional EBV-reactive T cells. By contrast, PP-reactive CD8+ T cells were primarily bi-functional (>60% at v1 and v2), produced IFN-γ and TNF and had more tri-functional than mono-functional components. We observed a moderate correlation between viral load and EBNA3A, EB-VLP, and PP-reactive CD8+ T cells (r All three EBV-derived antigen formulations represent innovative and generic recall antigens suitable for monitoring EBV-specific T-cell responses ex vivo. Their combined use facilitates a thorough analysis of EBV-specific T-cell immunity and allows the identification of functional T-cell signatures linked to disease development and severity.
Sections du résumé
BACKGROUND
BACKGROUND
Infection with the Epstein-Barr virus (EBV) elicits a complex T-cell response against a broad range of viral proteins. Hence, identifying potential differences in the cellular immune response of patients with different EBV-associated diseases or different courses of the same disorder requires interrogation of a maximum number of EBV antigens. Here, we tested three novel EBV-derived antigen formulations for their ability to reactivate virus-specific T cells ex vivo in patients with EBV-associated infectious mononucleosis (IM).
METHODS
METHODS
We comparatively analyzed EBV-specific CD4+ and CD8+ T-cell responses to three EBV-derived antigen formulations in 20 pediatric patients during the early phase of IM: T-activated EBV proteins (BZLF1, EBNA3A) and EBV-like particles (EB-VLP), both able to induce CD4+ and CD8+ T-cell responses ex vivo, as well as an EBV-derived peptide pool (PP) covering 94 well-characterized CD8+ T-cell epitopes. We assessed the specificity, magnitude, kinetics, and functional characteristics of EBV-specific immune responses at two sequential time points (v1 and v2) within the first six weeks after IM symptom onset (T
RESULTS
RESULTS
All three tested EBV-derived antigen formulations enabled the detection of EBV-reactive T cells during the early phase of IM without prior T-cell expansion in vitro. EBV-reactive CD4+ and CD8+ T cells were mainly mono-functional (CD4+: mean 64.92%, range 56.15-71.71%; CD8+: mean 58.55%, range 11.79-85.22%) within the first two weeks after symptom onset (v1) with IFN-γ and TNF-secreting cells representing the majority of mono-functional EBV-reactive T cells. By contrast, PP-reactive CD8+ T cells were primarily bi-functional (>60% at v1 and v2), produced IFN-γ and TNF and had more tri-functional than mono-functional components. We observed a moderate correlation between viral load and EBNA3A, EB-VLP, and PP-reactive CD8+ T cells (r
CONCLUSIONS
CONCLUSIONS
All three EBV-derived antigen formulations represent innovative and generic recall antigens suitable for monitoring EBV-specific T-cell responses ex vivo. Their combined use facilitates a thorough analysis of EBV-specific T-cell immunity and allows the identification of functional T-cell signatures linked to disease development and severity.
Identifiants
pubmed: 38877590
doi: 10.1186/s12985-024-02411-0
pii: 10.1186/s12985-024-02411-0
doi:
Substances chimiques
Antigens, Viral
0
Epitopes, T-Lymphocyte
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Informations de copyright
© 2024. The Author(s).
Références
Longnecker RM, Kieff E, Cohen JI. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013. p. 1898–959.
Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022;185(20):3652–70.
pubmed: 36113467
pmcid: 9529843
doi: 10.1016/j.cell.2022.08.026
Balfour HH Jr., Dunmire SK, Hogquist KA. Hogquist, Infectious mononucleosis. Clin Transl Immunology. 2015;4(2):e33.
pubmed: 25774295
pmcid: 4346501
doi: 10.1038/cti.2015.1
Dunmire SK, Verghese PS, Balfour HH Jr. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84–92.
pubmed: 29525635
doi: 10.1016/j.jcv.2018.03.001
Long HM, Meckiff BJ, Taylor GS. The T-cell Response to Epstein-Barr Virus-New Tricks From an Old Dog. Front Immunol. 2019;10:2193.
pubmed: 31620125
pmcid: 6759930
doi: 10.3389/fimmu.2019.02193
Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010;362(21):1993–2000.
pubmed: 20505178
doi: 10.1056/NEJMcp1001116
Papesch M, Watkins R. Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol Allied Sci. 2001;26(1):3–8.
pubmed: 11298158
doi: 10.1046/j.1365-2273.2001.00431.x
Okano M, Gross TG. Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection. Am J Med Sci. 2012;343(6):483–9.
pubmed: 22104426
doi: 10.1097/MAJ.0b013e318236e02d
Imashuku S, Morimoto A, Ishii E. Virus-triggered secondary hemophagocytic lymphohistiocytosis. Acta Paediatr. 2021;110(10):2729–36.
pubmed: 34096649
doi: 10.1111/apa.15973
Rowe KS. Long Term Follow up of Young People With Chronic Fatigue Syndrome Attending a Pediatric Outpatient Service. Front Pediatr. 2019;7:21.
pubmed: 30847333
pmcid: 6393360
doi: 10.3389/fped.2019.00021
Rowe PC, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Front Pediatr. 2017;5:121.
pubmed: 28674681
pmcid: 5474682
doi: 10.3389/fped.2017.00121
Ruiz-Pablos M, et al. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front Immunol. 2021;12:656797.
pubmed: 34867935
pmcid: 8634673
doi: 10.3389/fimmu.2021.656797
Bjornevik K, et al. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160–71.
pubmed: 36759741
doi: 10.1038/s41582-023-00775-5
Murray PG, Young LS. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood. 2019;134(7):591–6.
pubmed: 31186275
doi: 10.1182/blood.2019000568
Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.
pubmed: 35025605
doi: 10.1126/science.abj8222
Fournier B, Latour S. Immunity to EBV as revealed by immunedeficiencies. Curr Opin Immunol. 2021;72:107–15.
pubmed: 33989894
doi: 10.1016/j.coi.2021.04.003
Tangye SG, Latour S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood. 2020;135(9):644–55.
pubmed: 31942615
doi: 10.1182/blood.2019000928
Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol. 2012;19(1):14–20.
pubmed: 22123662
doi: 10.1097/MOH.0b013e32834daa08
Rezk E, et al. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev. 2015;2015(11):CD004402.
pubmed: 26558642
pmcid: 7047551
Abbott RJ, et al. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. J Virol. 2017;91(21):e00382.
pubmed: 28835490
pmcid: 5640854
doi: 10.1128/JVI.00382-17
Lam JKP, et al. Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection. Front Microbiol. 2018;9:416.
pubmed: 29599759
pmcid: 5863510
doi: 10.3389/fmicb.2018.00416
Calarota SA, et al. Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. J Clin Virol. 2015;70:109–19.
pubmed: 26305832
doi: 10.1016/j.jcv.2015.07.299
Tischer S, et al. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. J Immunol Methods. 2014;408:101–13.
pubmed: 24877879
doi: 10.1016/j.jim.2014.05.011
Holthaus L, et al. CD4(+) T cell activation, function, and metabolism are inhibited by low concentrations of DMSO. J Immunol Methods. 2018;463:54–60.
pubmed: 30201392
doi: 10.1016/j.jim.2018.09.004
Hadrup SR, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6(7):520–6.
pubmed: 19543285
doi: 10.1038/nmeth.1345
Newell EW, et al. Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods. 2009;6(7):497–9.
pubmed: 19543286
pmcid: 2731062
doi: 10.1038/nmeth.1344
Hislop AD, et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587–617.
pubmed: 17378764
doi: 10.1146/annurev.immunol.25.022106.141553
Cirac A, et al. Epstein-Barr virus strain heterogeneity impairs human T-cell immunity. Cancer Immunol Immunother. 2018;67(4):663–74.
pubmed: 29374782
pmcid: 11028080
doi: 10.1007/s00262-018-2118-z
Barabas S, et al. Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein. PLoS Pathog. 2008;4(11):e1000198.
pubmed: 18989461
pmcid: 2572144
doi: 10.1371/journal.ppat.1000198
Crisci E, Barcena J, Montoya M. Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol. 2012;148(3–4):211–25.
pubmed: 22705417
pmcid: 7112581
doi: 10.1016/j.vetimm.2012.04.026
Adhikary D, et al. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One. 2007;2(7):e583.
pubmed: 17611619
pmcid: 1894652
doi: 10.1371/journal.pone.0000583
Adhikary D, et al. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. J Virol. 2008;82(8):3903–11.
pubmed: 18272580
pmcid: 2293016
doi: 10.1128/JVI.02227-07
Adhikary D, et al. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med. 2006;203(4):995–1006.
pubmed: 16549597
pmcid: 2118290
doi: 10.1084/jem.20051287
Linnerbauer S, et al. Virus and Autoantigen-Specific CD4+ T Cells Are Key Effectors in a SCID Mouse Model of EBV-Associated Post-Transplant Lymphoproliferative Disorders. PLoS Pathog. 2014;10(5):e1004068.
pubmed: 24853673
pmcid: 4031221
doi: 10.1371/journal.ppat.1004068
Hoffmann D, et al. Elevated Epstein-Barr virus loads and lower antibody titers in competitive athletes. J Med Virol. 2010;82(3):446–51.
pubmed: 20087932
doi: 10.1002/jmv.21704
Feederle R, et al. Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative epstein-barr virus. J Virol. 2005;79(12):7641–7.
pubmed: 15919916
pmcid: 1143645
doi: 10.1128/JVI.79.12.7641-7647.2005
Delecluse HJ, et al. A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci U S A. 1999;96(9):5188–93.
pubmed: 10220441
pmcid: 21839
doi: 10.1073/pnas.96.9.5188
Körber N, et al. Validation of an IFNgamma/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med. 2016;14(1):175.
pubmed: 27297580
pmcid: 4906590
doi: 10.1186/s12967-016-0932-7
Koerber N, et al. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13(1):153.
pubmed: 35013191
pmcid: 8748966
doi: 10.1038/s41467-021-27649-y
Korber N, et al. Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24(high)CD38(high) Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders. Front Immunol. 2021;12:713351.
pubmed: 34566969
pmcid: 8461011
doi: 10.3389/fimmu.2021.713351
Cirac A, et al. Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven. Front Immunol. 2021;12:796379.
pubmed: 34975903
pmcid: 8716887
doi: 10.3389/fimmu.2021.796379
Korber N, et al. Evaluation of T-activated proteins as recall antigens to monitor Epstein-Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting. J Transl Med. 2020;18(1):242.
pubmed: 32552697
pmcid: 7298696
doi: 10.1186/s12967-020-02385-x
Adhikary D, et al. Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for Therapy. PLoS ONE. 2007;2:e583.
pubmed: 17611619
pmcid: 1894652
doi: 10.1371/journal.pone.0000583
Kuhne JF, et al. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors. Transpl Immunol. 2020;61:101291.
pubmed: 32330566
doi: 10.1016/j.trim.2020.101291
Taylor GS, et al. The immunology of epstein-barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821.
pubmed: 25706097
doi: 10.1146/annurev-immunol-032414-112326
Almeida JR, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med. 2007;204(10):2473–85.
pubmed: 17893201
pmcid: 2118466
doi: 10.1084/jem.20070784
Johannsen E, et al. Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A. 2004;101(46):16286–91.
pubmed: 15534216
pmcid: 528973
doi: 10.1073/pnas.0407320101
Apostolidis SA, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990–2001.
pubmed: 34522051
pmcid: 8604727
doi: 10.1038/s41591-021-01507-2
van Zyl DG, et al. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog. 2018;14(12):e1007464.
pubmed: 30521644
pmcid: 6298685
doi: 10.1371/journal.ppat.1007464
Dowell AC, et al. Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors. PLoS Pathog. 2021;17(12):e1010137.
pubmed: 34882759
pmcid: 8691624
doi: 10.1371/journal.ppat.1010137
Meckiff BJ, et al. Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4(+) T Cells. J Immunol. 2019;203(5):1276–87.
pubmed: 31308093
pmcid: 6697742
doi: 10.4049/jimmunol.1900377
Choi SM, et al. Cellular heterogeneity of circulating CD4(+)CD8(+) double-positive T cells characterized by single-cell RNA sequencing. Sci Rep. 2021;11(1):23607.
pubmed: 34880348
pmcid: 8655006
doi: 10.1038/s41598-021-03013-4
Anderson CK, Brossay L. The role of MHC class Ib-restricted T cells during infection. Immunogenetics. 2016;68(8):677–91.
pubmed: 27368413
pmcid: 5003733
doi: 10.1007/s00251-016-0932-z
Palmer WH, et al. Human herpesvirus diversity is altered in HLA class I binding peptides. Proc Natl Acad Sci U S A. 2022;119(18):e2123248119.
pubmed: 35486690
pmcid: 9170163
doi: 10.1073/pnas.2123248119
Smith CA, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4(2):73–9.
pubmed: 7633844
doi: 10.1089/scd.1.1995.4.73
Hislop AD, et al. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195(7):893–905.
pubmed: 11927633
pmcid: 2193726
doi: 10.1084/jem.20011692
Long HM, et al. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med. 2013;210(5):933–49.
pubmed: 23569328
pmcid: 3646497
doi: 10.1084/jem.20121437
Forrest C, et al. Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection. PLoS Pathog. 2018;14(9):e1007110.
pubmed: 30248160
pmcid: 6171963
doi: 10.1371/journal.ppat.1007110
Patil VS, et al. Precursors of human CD4(+) cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci Immunol. 2018;3(19):eaan8664.
pubmed: 29352091
pmcid: 5931334
doi: 10.1126/sciimmunol.aan8664
Tamura Y, et al. Concomitant Cytotoxic Effector Differentiation of CD4(+) and CD8(+) T Cells in Response to EBV-Infected B Cells. Cancers (Basel). 2022;14(17):4118.
pubmed: 36077655
doi: 10.3390/cancers14174118
Adhikary D, et al. The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4(+) T Cells. J Virol. 2020;94(15):e00284.
pubmed: 32461311
pmcid: 7375367
doi: 10.1128/JVI.00284-20
Cui X, Snapper CM. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front Immunol. 2021;12:734471.
pubmed: 34691042
pmcid: 8532523
doi: 10.3389/fimmu.2021.734471